It had, therefore, been hypothesized that enhancement is a marker of more aggressive disease, and by extrapolation that the tumor had likely developed growth mechanisms that were distinct from those enabled by the IDH mutation, making the latter a less attractive therapeutic target in high-grade tumors. Here, IDH1 is linked to neoplasm.